Cholinesterase inhibitors Dotaz Zobrazit nápovědu
Alzheimer disease & associated disorders, ISSN 0893-0341 vol. 20, no. 2, suppl. 1, April-June 2006
26 s. : il., tab. ; 28 cm
- MeSH
- Alzheimerova nemoc terapie MeSH
- cholinesterasové inhibitory MeSH
- medicína založená na důkazech MeSH
- Publikační typ
- sborníky MeSH
- Konspekt
- Patologie. Klinická medicína
- NLK Obory
- neurologie
- psychiatrie
Autoři podávají praktický pohled na léčbu demence inhibitory cholinesteráz (ICHE). Podávají jejich stručný přehled. Vyjadřují se k očekávání výsledků léčby. Oceňují terapeutický pokrok, který zavedení inhibitorů cholinesteráz - donepezilu, galantaminu a rivastigminu - přineslo. Nastiňují problémy, které mohou nastat v praxi, a to zejména v důsledku zásahu do cholinergního metabolizmu, nebo v souvislosti s možnými interakcemi, a to jak interakcemi mezi inhibitory cholinesteráz a jinými podávanými léky, tak i inhibitory a přítomnými tělesnými nemocemi provázejícími často vyšší věk. Autoři uvádějí, že správný výběr léku a odpovídající monitorování rizikových veličin vede ke zvýšení komfortu jak nemocných, tak i personálu.
Authors give practical view into a treatment of dementia with cholinesterase inhibitors and brief list is presented. They also express treatment expectations too. Authors appreciate therapeutic advance brought form introduction of cholinesterase inhibitors - donepezil, galantamine and rivastigmine. Presented problems can rise in practice mostly from interference with cholinergic metabolism or due to other possible interactions between cholinesterase inhibitors and other drugs or interactions between inhibitors and somatic disease linked with elderly. Authors state, that correct choice of a drug and appropriate monitoring of risks factors increases either patients- and staff-s comfort.
- MeSH
- Alzheimerova nemoc farmakoterapie MeSH
- cholinesterasové inhibitory aplikace a dávkování farmakologie škodlivé účinky MeSH
- demence farmakoterapie MeSH
- galantamin aplikace a dávkování farmakologie MeSH
- hodnocení rizik MeSH
- lékové interakce MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
- MeSH
- cholinesterasové inhibitory otrava MeSH
- cholinesterasy terapeutické užití MeSH
- dospělí MeSH
- hemoperfuze MeSH
- insekticidy otrava MeSH
- lidé MeSH
- organofosforové sloučeniny MeSH
- otrava organofosfáty MeSH
- otrava etiologie terapie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
Acta neurologica scandinavica ; Supplementum Vol. 88. 149
65 s. : tab., grafy ; 28 cm
- Konspekt
- Lékařské vědy. Lékařství
- NLK Obory
- neurologie
- psychiatrie
It was with interest and pleasure that I read the contribution of Petronilho & Figueroa-Villaret in the MMSL reviewing the literature on agents for defense against chemical warfare [Petronilho & Figueroa-Villaret, 2015]. The authors briefly touch on the history of organophosphates emphasizing the pioneering contribution of Jean Louis Lassaigne, the synthesis of triethyl- phosphate (TEP) and finally the achievements of Philippe de Clermont who codeveloped the first organophosphate (OP) acetylcholinesterase inhibitor, tetraethyl pyrophosphate (TEEP). They continue by pointing out that Wilson and Ginsburg managed to reactivate OP-inhibited acetylcholinesterase using pralidoxime (2 -PAM), which reactivates the enzyme much faster than hydroxylamine. I believe that the scientists involved in organophosphorus cholinesterase inhibitor & reactivator development deserve more attention and that the colleagues’ contribution contains a number of ambiguities deserving additional.
The work deals with the design, synthesis and biolog-icalactivityofnewcarbamatecholinesteraseinhibitors.Itis focused on selected syntheses of new carbamate deriva-tives, which were tested for their anticholinesterase activi-ty against acetylcholinesterase as well as butyrylcholines-terase. Despite various theories in the pathogenesis of Alz-heimer's disease, drugs that can inhibit these two enzymes still represent the major approach to the treatment of this neurodegenerative disease. Many of the newly synthesized compounds have unique chemical structure. Recently, the approach to the synthesis of new cholinesterase inhibitors has focused on the preparation of potential drugs, contain-ing in their chemical structure fragments of already known drugs, commonly used in the pharmacotherapy of Alzhei-mer's disease, but also other diseases. The aim of prepar-ing these compounds is to affect several biological systems simultaneously. These multipotent compounds have been termed "multi-target-directed ligands"; the molecules of drugs used to treat Alzheimer's disease always contain a pharmacophore acting as a cholinesterase inhibitor, which represents the mainstay of therapy
- MeSH
- acetylcholinesterasa MeSH
- Alzheimerova nemoc diagnóza farmakoterapie patologie MeSH
- butyrylcholinesterasa MeSH
- cholinesterasové inhibitory * chemie farmakologie terapeutické užití MeSH
- karbamáty chemie terapeutické užití MeSH
- lidé MeSH
- rivastigmin analogy a deriváty terapeutické užití MeSH
- vyvíjení léků metody MeSH
- Check Tag
- lidé MeSH
Natural cholinesterase inhibitors were found in many biological sources: bacteria, blue-greens, plants, marine sponges, microscopic fungus, and in a smaller scale also in mushrooms, fruiting body of macroscopis fungus. Only cholinesterase inhibitors isolated from mushrooms are subjects of this minireview. These natural compounds with anticholinergic activity may be considered as prospective drugs against Alzheimer's disease.
- MeSH
- acetylcholinesterasa účinky léků MeSH
- Agaricales enzymologie MeSH
- Agaricus enzymologie MeSH
- Alzheimerova nemoc enzymologie farmakoterapie MeSH
- biologické přípravky farmakologie chemie MeSH
- butyrylcholinesterasa účinky léků MeSH
- cholinesterasové inhibitory farmakologie chemie terapeutické užití MeSH
- Cortinarius enzymologie MeSH
- léčivé rostliny MeSH
- lidé MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
